Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

NICE backs NHS use of Pfizer’s PARP inhibitor Talzenna in HER2-, BRCA+ advanced breast cancer, the first targeted therapy for these patients.